Charlotte Chung

Company: Voyager Therapeutics

Job title: Director, Research

Seminars:

9:00 P-tau217: Clinical Promise, Regulatory Hurdles & the Path to Surrogate Endpoint Status 9:00 am

Highlighted by the recent approval of the first in vivo blood test for Alzheimer’s Disease, advancements in new technologies to measure p-tau217 are at an all-time-high. Join this session for an inside look on how p-tau217 is setting the gold standard in AD diagnostics, exploring its scientific evolution, clinical impact, and regulatory breakthrough, offering a…Read more

day: Pre-Conference Workshop Day